Literature DB >> 11096699

Acute Ischemic Stroke.

.   

Abstract

Patients with acute ischemic stroke should be immediately transported to the nearest hospital for rapid evaluation and treatment. Intravenous t-PA within 3 hours of symptom onset is the recommended treatment for patients who meet the National Institute of Neurological Disorders and Stroke (NINDS) study eligibility criteria. Patients should be informed of the risk of symptomatic cerebral hemorrhage, and strict adherence to the NINDS study protocol is strongly recommended to optimize the risk-benefit ratio. Ischemic stroke patients who are not eligible for t-PA therapy should usually be started on aspirin. Intravenous heparin is not recommended as a standard treatment but may be considered for specific patient subgroups. Low-dose subcutaneous heparin is recommended for prophylaxis of deep vein thrombosis in immobilized patients. Management of stroke patients by a designated stroke team is recommended to facilitate prompt diagnosis and treatment and early initiation of rehabilitation therapy. We also recommend that physicians who manage patients with acute stroke maintain contact with local or regional stroke centers to facilitate referral of appropriate patients for intensive care or specialized diagnostic tests or therapies.

Entities:  

Year:  1999        PMID: 11096699     DOI: 10.1007/s11940-999-0009-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  46 in total

Review 1.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  G W Albers; J D Easton; R L Sacco; P Teal
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

2.  Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke.

Authors:  S Wildermuth; M Knauth; T Brandt; R Winter; K Sartor; W Hacke
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

3.  Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI.

Authors:  G Rordorf; W J Koroshetz; W A Copen; S C Cramer; P W Schaefer; R F Budzik; L H Schwamm; F Buonanno; A G Sorensen; G Gonzalez
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

4.  Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion.

Authors:  S Nakano; K Yokogami; H Ohta; T Yano; T Ohnishi
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

5.  Early hemicraniectomy in patients with complete middle cerebral artery infarction.

Authors:  S Schwab; T Steiner; A Aschoff; S Schwarz; H H Steiner; O Jansen; W Hacke
Journal:  Stroke       Date:  1998-09       Impact factor: 7.914

6.  Heparin treatment in sinus venous thrombosis.

Authors:  K M Einhäupl; A Villringer; W Meister; S Mehraein; C Garner; M Pellkofer; R L Haberl; H W Pfister; P Schmiedek
Journal:  Lancet       Date:  1991-09-07       Impact factor: 79.321

7.  Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT.

Authors:  T Ueda; T Hatakeyama; Y Kumon; S Sakaki; T Uraoka
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

8.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

9.  Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.

Authors:  H P Adams; T G Brott; A J Furlan; C R Gomez; J Grotta; C M Helgason; T Kwiatkowski; P D Lyden; J R Marler; J Torner; W Feinberg; M Mayberg; W Thies
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

10.  Agreement on disease-specific criteria for do-not-resuscitate orders in acute stroke. Members of the Canadian and Western New York Stroke Consortiums.

Authors:  A V Alexandrov; P M Pullicino; E M Meslin; J W Norris
Journal:  Stroke       Date:  1996-02       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.